Drug Trial Radar · NCT07831902
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
Dec 2030
Study completion Dec 2034
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with high-risk NSMP endometrial cancer. Patients will be randomised to radiotherapy with chemotherapy (standard of care), or radiotherapy followed by oral progestin tablets.
Conditions
- Endometrial Cancer
- Uterine Neoplasms
Interventions
medroxyprogesterone acetate tablets OR megestrol acetateDrug
Medroxyprogesterone acetate 200mg once daily OR megestrol acetate 160mg once daily following completion of radiotherapy, for 24 months (2 years)
CisplatinDrug
carboplatin and paclitaxel +/- cisplatin, as per standard of care/investigator decision, with radiotherapy
Carboplatin + PaclitaxelDrug
carboplatin and paclitaxel +/- cisplatin, as per standard of care/investigator decision, with radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence free survival (RFS)Time frame: 3 years
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Royal United Hospitals Bath
Bath, United Kingdom · Recruiting
Cheltenham General
Cheltenham, United Kingdom · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Recruiting
Bartholemew's Hospital
London, United Kingdom · Recruiting
Royal Marsden (Chelsea)
London, United Kingdom · Recruiting
University College London Hospital (UCLH)
London, United Kingdom · Recruiting
The Christie
Manchester, United Kingdom · Recruiting
James Cook University Hospital
Middlesbrough, United Kingdom · Recruiting
Churchill
Oxford, United Kingdom · Recruiting
Queen Alexandra Hospital
Portsmouth, United Kingdom · Recruiting
University Hospital Southampton
Southampton, United Kingdom · Recruiting
Royal Marsden (Sutton)
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.